Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Modeling the metabolic interplay between a parasitic worm and its bacterial endosymbiont allows the identification of novel drug targets

ABSTRACT: The filarial nematode Brugia malayi represents a leading cause of disability in the developing world, causing lymphatic filariasis in nearly 40 million people. Currently available drugs are not well-suited to mass drug administration efforts, so new treatments are urgently required. One potential vulnerability is the endosymbiotic bacteria Wolbachia—present in many filariae—which is vital to the worm. Genome scale metabolic networks have been used to study prokaryotes and protists and have proven valuable in identifying therapeutic targets, but only recently have been applied to eukaryotic organisms. Here, we present iDC625, the first compartmentalized metabolic model of a parasitic worm. We used this model to show how metabolic pathway usage allows the worm to adapt to different environments, and predict a set of 99 reactions essential to the survival of B. malayi. We validated three of those reactions with drug tests and demonstrated novel antifilarial properties for all three compounds.

ORGANISM(S): Brugia Malayi Roundworm

TISSUE(S): Worms

DISEASE(S): Lymphatic Filariasis

SUBMITTER: Drew Jones

PROVIDER: ST001258 | MetabolomicsWorkbench | Mon Sep 23 00:00:00 BST 2019

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

Investigating delayed-onset Drug Hypersensitivity Reactions Prospectively

Project description:Investigating delayed-onset Drug Hypersensitivity Reactions Prospectively

| PRJNA994263 | ENA

Investigating delayed-onset Drug Hypersensitivity Reactions Prospectively

Project description:Investigating delayed-onset Drug Hypersensitivity Reactions Prospectively

| PRJNA994264 | ENA

Transcriptomic profiling and epigenetic analysis of primary human monocyte-to-macrophage differentiation in context of metabolic modeling

Project description:Fast reconstruction of cell type-specific metabolic models and understanding the underlying epigenetic regulation will be increasingly important for personalized medicine. To enable fast creation of high-quality metabolic models from gene expression data, we have developed a new workflow named FASTCORMICS. FASTCORMICS is devoid of arbitrary parameter settings and outperforms its competitors in speed with comparable accuracy. To better understand the cell type-specific regulation of the alternative metabolic pathways we built multiple metabolic models based on microarray analysis at 4 different time points during differentiation of primary human monocytes to macrophages and performed ChIP-Seq experiments to map the active enhancers in macrophages. Focusing on the metabolic genes under high regulatory load from multiple enhancers or super-enhancers, we found these genes to show the most cell type-restricted and abundant expression profiles within their respective pathways. Importantly, the high regulatory load genes are enriched for transport reactions and other pathway entry points, suggesting that they are the critical regulatory control points for cell type-specific metabolism.

2016-03-02 | E-MTAB-3089 | biostudies-arrayexpress

Rattus norvegicus

Project description:Profiling of D-PA Induced Idiosyncratic Drug Reactions

| PRJNA92385 | ENA

Computational modeling integrating transcriptomic and vulnerability responses can predict suppressors of cell death as candidate targets for cancer therapy

Project description:Identification of novel target genes for cancer therapy is a significant challenge of biomedical research. Here, we describe a computational pipeline, which integrates transcriptomic and vulnerability responses to cell-death inducing drugs, to predict repressors of cell-death as candidate targets for cancer therapy. The candidate target genes were predicted based on two modules: the transcriptomic similarity and the correlation modules. The transcriptomic similarity module identified genes whose targeting results in similar transcriptomic responses of the death-inducing drugs, while the correlation module identified candidate genes whose expression was correlated to the vulnerability to the death-inducing drugs. The combined predictors generated by these two modules were integrated into a single ranked metric. As a proof-of-concept, we selected ferroptosis inducers as death-inducing drugs, and triple negative breast cancer as a cancer model. The pipeline could predict candidate genes as ferroptosis repressors, as demonstrated by computational and experimental validation, including experimental data of 9 representative genes, thus, highlighting the robustness and power of this pipeline. The described pipeline can be used to identify repressors of different cell-death pathways as potential therapeutic targets for various cancer types.

2024-09-05 | GSE255459 | GEO

Integrative analysis of patient-derived tumoroids and ex vivo organoid modeling of ARID1A loss in bladder cancer reveals therapeutic molecular targets

Project description:Somatic mutations in ARID1A (AT-rich interactive domain-containing protein 1A) are present in approximately 25% of bladder cancers (BC) and are associated with poor prognosis. With a view to discover effective treatment options for ARID1A-deficient BC patients, we set out to identify targetable effectors dysregulated consequent to ARID1A deficiency. Integrative analyses of ARID1A depletion in normal organoids and data mining in publicly available datasets revealed upregulation of DNA repair and cell cycle-associated genes consequent to loss of ARID1A and identified CHEK1 (Checkpoint kinase 1) and chromosomal passenger complex member BIRC5 (Baculoviral IAP Repeat Containing 5) as therapeutically drug-able candidate molecular effectors. Ex vivo treatment of patient-derived BC tumoroids with clinically advanced small molecule inhibitors targeting CHEK1 or BIRC5 was associated with increased DNA damage signalling and apoptosis, and selectively induced cell death in tumoroids lacking ARID1A protein expression. Thus, integrating public datasets with patient-derived organoid modelling and ex-vivo drug testing can uncover key molecular effectors and mechanisms of oncogenic transformation, potentially leading to novel therapeutic strategies. Our data point to ARID1A protein expression as a suitable candidate biomarker for the selection of BC patients responsive to therapies targeting BIRC5 and CHEK1.

2024-11-07 | GSE271565 | GEO

Modeling Diabetic Endothelial Dysfunction with Patient-Specific Induced Pluripotent Stem Cells

Project description:Diabetes is a known risk factor for various cardiovascular complications, mediated by endothelial dysfunction. Despite the high prevalence of this metabolic disorder, there is a lack of in vitro models that recapitulate the complexity of genetic and environmental factors associated with diabetic endothelial dysfunction. Here, we utilized human induced pluripotent stem cell (iPSC)-derived endothelial cells (ECs) to develop in vitro models of diabetic endothelial dysfunction. We found that the diabetic phenotype was recapitulated in diabetic patient-derived iPSC-ECs, even in the absence of a diabetogenic environment. Subsequent exposure with culture conditions that mimic the diabetic clinical chemistry induced a diabetic phenotype in healthy iPSC-ECs but did not affect the already dysfunctional diabetic iPSC-ECs. RNA-seq analysis revealed extensive transcriptome-wide differences between cells derived from healthy individuals and diabetic patients. The in vitro disease models were used as a screening platform which identified angiotensin receptor blockers (ARBs) that improved endothelial function in vitro for each patient. In summary, we present in vitro models of diabetic endothelial dysfunction using iPSC technology, taking into account the complexity of genetic and environmental factors in the metabolic disorder. Our study provides novel insights into the pathophysiology of diabetic endothelial dysfunction and highlights the potential of iPSC-based models for drug discovery and personalized medicine.

2023-07-05 | GSE236430 | GEO

Functional multi-organelle units control inflammatory lipid metabolism of macrophages

Project description:Eukaryotic cells contain several membrane-separated organelles to compartmentalize distinct metabolic reactions. However, it has remained unclear how these organelle systems are coordinated, when cells adapt metabolic pathways to support their development, survival or effector functions. Here we present OrgaPlexing, a multispectral organelle imaging approach for the comprehensive mapping of six key metabolic organelles and their interactions. We use this analysis on macrophages, immune cells that undergo rapid metabolic switches upon sensing bacterial and inflammatory stimuli. Our results identify lipid droplets (LDs) as primary inflammatory responder organelle, which forms three- and four-way interactions with other organelles. While clusters with endoplasmic reticulum (ER) and mitochondria (M-ER-LD unit) help supply fatty acids for LD growth, the additional recruitment of peroxisomes (M-ER-P-LD unit) supports fatty acid efflux from LDs. Interference with individual components of these units has direct functional consequences for inflammatory lipid synthesis. Together, we show that macrophages form functional multi-organellar units (MOUs) to support metabolic adaptation, and provide an experimental strategy to identify organelle-metabolic signaling hubs.

2024-05-03 | GSE235484 | GEO

Three-way combinatorial CRISPR screen for analyzing interactions among druggable targets

Project description:We present a CRISPR-based multi-gene knockout screening system and new toolkits for extensible assembly of barcoded high-order combinatorial guide RNA libraries en masse. We apply this system for systematically identifying not only pairwise but also three-way synergistic therapeutic target combinations, and successfully validated double and triple combination regimens for suppression on cancer cell growth and protection against Parkinson’s disease-associated toxicity. This system overcomes the practical challenges to experiment on a large number of high-order genetic and drug combinations, and is applicable for uncovering the rare synergistic interactions between druggable targets.

2020-08-11 | GSE154112 | GEO

Identifying metabolic adaptations of rat cardiomyocytes in response to cardiotoxicity

Project description:Improvements in the diagnosis and treatment of cancer has revealed the long-term side effects of chemotherapeutics, particularly cardiotoxicity. Current clinical measures to track cardiotoxicity are insufficient to diagnose damage before it has been done, necessitating new, early biomarkers of cardiotoxicity. Here, we collected paired transcriptomics and metabolomics data characterizing in vitro cardiotoxicity to three compounds: 5-fluorouracil, acetaminophen, and doxorubicin. Standard gene enrichment and metabolomics approaches identify some commonly affected pathways and metabolites but are not able to readily identify mechanisms of cardiotoxicity. Here, we integrate this paired data with a genome-scale metabolic network reconstruction (GENRE) of the heart to identify shifted metabolic functions, unique metabolic reactions, and changes in flux in metabolic reactions in response to these compounds. Using this approach, we are able to confirm known mechanisms of doxorubicin-induced cardiotoxicity and provide hypotheses for mechanisms of cardiotoxicity for 5-fluorouracil and acetaminophen.

2021-06-01 | GSE166957 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data